Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Assessment of the effects of skin microneedling as adjuvant therapy for facial melasma: a pilot study

  • 1,
  • 1,
  • 2 and
  • 3, 4Email author
BMC DermatologyBMC series – open, inclusive and trusted201717:14

https://doi.org/10.1186/s12895-017-0066-5

©  The Author(s). 2017

  • Received: 11 April 2017
  • Accepted: 21 November 2017
  • Published:
Open Peer Review reports

Abstract

Background

Melasma is a common chronic and relapsing acquired dyschromia. Skin microneedling was reported resulting sustained long-term improvement of recalcitrant melasma, however, the exact mechanism that promotes this skin lightening is not known. This study aimed to investigate clinical and histologic alterations promoted by skin microneedling in facial melasma.

Methods

Open pilot trial including six women with facial refractory melasma submitted to two sessions of microneedling (1.5 mm) each 30 days followed by daily triple combination and broad-spectrum sunscreen. Comparison of pretreatment (T0) and 15 days after last microneedling procedure (T45) was made by standardized pictures, skin colorimetry, MASI, MELASQoL and histological parameters (haematoxylin-eosin, picrosirius-red, periodic acid Schiff and Fontana-Masson staining).

Results

The age of the subjects varied from 34 to 46 years-old, the phototypes were III and IV (Fitzpatrick), and age of melasma onset was 20 to 38 years. Improvement of melasma was perceived in all subjects. There was a significant reduction of MASI score (−70%), MELASQoL (−55%) and increase in L* (+13%) colorimetric value (p < 0.03). All cases evidenced epithelium thickening, decrease in melanin pigmentation and densification of upper dermis collagen (p = 0.03). Patients were followed by 6 months under broad-spectrum sunscreen and triple combination without relapse.

Conclusion

In addition to classic treatment (broad-spectrum sunscreen and triple combination), skin microneedling promoted clinical and histological improvement of refractory facial melasma.

Keywords

  • Melasma
  • Treatment
  • Microneedling
  • Quality of life
  • Masi

Background

Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years [1, 2].

Due to its high prevalence, the involvement of visible photoexposed areas - such as the face, in patients at a competitive age, and the relative resistance to treatment, melasma inflicts major impact on quality of life [3–5].

Its pathogenesis is not fully understood, nevertheless there is evidence that melanogenesis in melasma differ from tanning and post-inflammatory hyperpigmentation as well as there is an involvement of the whole epidermal melanin unit in the process (not just hypertrophic melanocytes), mastocytes, fibroblast and endothelium derived cytokines, as well as there are upper dermal abnormalities different from other acquired pigmentary disorders [6–8].

Skin microneedling, or percutaneous collagen induction by needles, is a minimally invasive procedure that uses short fine needles to puncture the skin and stimulates fibroblast proliferation, release of growth factors and collagen production [9–11]. Long-term improvement of recalcitrant melasma after microneedling was reported in one case series, however, the exact mechanism that promotes skin lightening is not known [12, 13].

This study has investigated clinical and histologic alterations promoted by skin microneedling in facial melasma.

Methods

We performed an open pilot trial including women with facial refractory facial melasma, without specific treatment besides sunscreen for the last 30 days.

Refractory melasma was considered those with more than 5 years of evolution and relapsing to more than three attempting to treatment, including triple combination (hydroquinone, fluocinolone and tretinoin).

After consent, they were submitted to two sessions of microneedling (Dr. Roller™, 1.5 mm) each 30 days (T0 and T30), followed (at the next day) by daily triple combination (Tri-Luma, Galderma) application and broad-spectrum sunscreen (Anthelios Airlicium SPF 70 com cor, La Roche Posay), according to Lima protocol [13].

Standardised pictures, colorimetry (LED quasi-L*a*b*), skin biopsies (3 mm punch), MASI scores (range 0–48) and MelasQoL-PB questionnaire were taken at the inclusion visit (T0) and T45 [14–16]. The paraffin-embedded skin specimens were processed by haematoxylin-eosin, picrosirius-red, periodic acid Schiff and Fontana-Masson staining.

The study was performed at Santa Casa de Misericórdia (Recife-PE, Brazil), from October to November 2016, and was approved by institutional board review (Comitê de Ética em Pesquisa da Faculdade de Medicina de Botucatu-Unesp).

Variables were compared between T0 and T45 by paired Student’s t or Wilcoxon test if normality was not indicated by Shapiro-Wilk procedure [17].

Data was analysed at IBM-SPSS 24 and significance was set as two-sided p < 0.05 [18].

Sample size was calculated to detect at least 30% reduction of values of MASI scores between the visits, with an effect size (mean / standard deviation) of 1.1, alpha error of 0.05 and 80% of power [19].

Results

The age of the subjects varied from 34 to 46 years-old, Fitzpatrick´ phototypes were III and IV, they reported 0 to 4 childbirths, daily time of direct sun exposure was 2 to 4 h, age of melasma onset was 20 to 38 years and MASI ranged from 29 to 46.

All participants have treated melasma previously with triple combination and others hydroquinone-free bleaching agents, with relapse.

After two sessions of microneedling, improvement of melasma was perceived in all subjects (Figs. 1 and 2), in addition, there was a subjective report of overall facial skin smoothness and greater radiance by the participants.
Fig. 1
Fig. 1

Facial melasma: a Pre-treatment (T0). b Post-treatment after two sessions of microneedling, triple combination, and broad-spectrum sunscreen (T45)

Fig. 2
Fig. 2

Facial melasma: a Pre-treatment (T0). b Post-treatment after two sessions of microneedling, triple combination, and broad-spectrum sunscreen (T45)

Clinical, quality of life and colorimetric measures at T0 and T45 are presented at Table 1. A 70% mean decrease in MASI, 13% increase in luminance (L*) and 55% decrease in MELASQoL were noticeable.
Table 1

Clinical, quality of life and colorimetric measures of melasma before and after two sessions of microneedling (n = 6)

 

Pre-treatment (T0)

Post-treatment (T45)

p-value

MASI

37.1 (8.2)

11.0 (2.9)

0.001

Colorimetry

 L*

43.5 (3.4)

49.2 (2.5)

0.015

 a*

20.7 (6.6)

15.5 (4.3)

0.237

 b*

32.0 (3.5)

28.2 (2.6)

0.040

 ITAo

−11.5 (6.3)

−1.7 (4.4)

0.028

MELASQoL

70 (68–70)

32 (22–41)

0.027

MASI Melasma Severity Index, ITA o Individual Typology Angle, MELASQoL Melasma Quality of Life Scale

Histologically (Figs. 3 and 4), all cases evidenced epithelium thickening, decrease in epithelial melanin pigmentation and densification of upper dermis collagen (p = 0.03). Basement membrane (Fig. 5) was damaged in melasma, and there are traces of basement membrane restoration after the treatment.
Fig. 3
Fig. 3

Fontana-Masson staining. a Pre-treatment (T0). b Post-treatment (T45), evidencing acanthosis and decrease in melanin density and the size of granules

Fig. 4
Fig. 4

Picrosirius red staining. a Pre-treatment (T0). b Post-treatment (T45), evidencing upper dermal dense collagen bundles

Fig. 5
Fig. 5

Periodic acid Schiff staining. a Pre-treatment (T0). b Post-treatment (T45), evidencing previous severe damaging followed by traces of restoration in the basement membrane zone

Patients were followed by 6 months under broad-spectrum sunscreen and triple combination without relapse.

Discussion

This is the first preliminary study that investigated clinical, quality of life, colorimetric and histological improvement in facial melasma with the addition of microneedling to the classic treatment.

In a historical comparison with a Brazilian population (n = 50) submitted to a regimen of broad-spectrum sunscreen and triple combination for 8 weeks, there was a mean MELASQoL reduction from 44.4 to 24.3 (45%) and a median MASI reduction from 13.1 to 3.2 (75%) [20]. Nevertheless, that sample had a less severe melasma than our patients, there were no reports of previous treatment relapses and the intervention lasted 25% more than our study (60 vs. 45 days).

Beyond clinical and quality of life improvement, epidermal melanin reduction, basement membrane restoration and increase in upper dermal collagen were evidenced. Basal membrane is damaged in melasma, as there are solar elastosis and collagen fragmentation what lead to the hypothesis of great activity of metalloproteinases [1–3, 9] and in upper dermis and decrease in type I collagen synthesis [8, 21–23].

Microneedling is classically indicated in the treatment of striae distensae, acne scars and photoaging, but its indications are widening among dermatologists [24, 25]. Some patients with acne scars perceived improvement in their melasma after microneedling, what motivated us to study a specific treatment regimen for them [13]. As it promote fibroblast proliferation and upper dermal collagenesis, microneedling can restore upper dermal and basal membrane damage in melasma, disfavouring the contact of melanocytes with dermal released melanogenic stimuli as endothelin, stem cell factor and hepatocyte growth factor [8, 22, 26, 27]. Additionally, a thickener epidermis can promote additional protection against UV damage.

In a previous histological study of triple association in melasma, the thickening of epidermis as well as upper dermal changes were not evidenced after 6 months of treatment [28]. This reinforces that the results we found in this preliminary study were induced by microneedling. Moreover, there is an increase in transepidermal drug delivery, for, at least, 72 h after the procedure. This can also increase the effect of triple association on the melanogenesis [29, 30].

Microneedling additional effects were suggested in a randomised controlled study with 60 patients comparing intradermal tranexamic acid versus its delivery by microneedling in facial melasma. There were respectively 36% and 44% improvement in MASI scores, moreover, 26% versus 41% of patients achieved 50% of MASI reduction [31]. Microneedling with vitamin C also resulted in a better clinical response followed Q-switched Nd:Yag for facial melasma, in a split-face trial with 16 patients [32].

Gentle dermabrasion with dental motor roller provided persistent clearance of melasma in 97% of 410 patients in a Thai case series [33]. The mechanism of dermabrasion related improvement of melasma was also not understood, however, as well as microneedling it promotes upper dermal neocollagenesis.

This study has potential limitations. It was performed in a single centre in the Northeast of Brazil (8°03′14″S and 34°52′52″W). Nevertheless, it is a sunny tropical city, what would disfavour the long-term remission observed at our follow up. The small sample size proposed in this pilot study also did not hamper we reach statistically significant results due to the consistency of the alterations induced by the treatment, as well as the main objective was to quantify clinical and histological alterations induced by microneedling in facial melasma. Finally, the addition of triple combination or the lack of a control group doesn’t allow to assess the effect of isolated microneedling in the treatment, nonetheless, these histological findings were not reported after triple combination and they make sense in the reversion of melasma pathogenetic issues. Moreover, microneedling can facilitate drug delivery of bleaching actives [28, 34, 35].

Conclusions

In addition to classic treatment (broad-spectrum sunscreen and triple combination), skin microneedling promoted clinical and histological improvement of recalcitrant facial melasma. Further randomised controlled studies are warranted to investigate treatment regimens of microneedling in order to maximize its efficacy, as long-term maintenance of the results.

Abbreviations

ITAo : 

Individual Typology Angle

MASI: 

Melasma Area Severity Index

MELASQoL: 

Melasma Quality of Life Scale

Declarations

Acknowledgements

We thank the patients for their cooperation and all the technicians involved in this work.

We’d also like to acknowledge Dr. Amit Pandya and Raja Sivamani for the careful revision and pertinent suggestions to this manuscript.

Funding

No funding

Availability of data and materials

Data from this study are freely available and can be obtained by contacting the corresponding author.

Authors’ contributions

EAL Data collection, final text composition and approval. MPP Data analysis, statistical analysis, final text composition and approval. MMAL Data collection, final text approval. HAM Data analysis, statistical analysis, final text composition and approval.

Ethics approval and consent to participate

This study has been approved by the Institutional Committee on Clinical Investigation (no 1.602.185).

Written informed consent was obtained from the patients to participate in this study and its publication and any accompanying images.

The study was performed at Santa Casa de Misericórdia (Recife-PE, Brazil), from October to November 2016, and was approved by institutional board review (Comitê de Ética em Pesquisa da Faculdade de Medicina de Botucatu-Unesp).

Consent for publication

Written informed consent was obtained from patients to participate in this study and its publication and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Santa Casa de Misericórdia, Praça Fleming, 35/1201 Jaqueira, Recife, PE, 52050-180, Brazil
(2)
UNIFESP, São Paulo, SP, Brazil
(3)
Unesp Medical School, Botucatu, SP, Brazil
(4)
Departamento de Dermatologia, SN, Campus da Unesp, Botucatu, SP, 18618-000, Brazil

References

  1. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014;89(5):771–82. doi:10.1590/abd1806-4841.20143063.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am Acad Dermatol. 2011;65(4):689-697. doi:doi:10.1016/j.jaad.2010.12.046.
  3. D'Elia MP, Brandao MC, de Andrade Ramos BR, da Silva MG, Miot LD, Dos Santos SE, et al. African ancestry is associated with facial melasma in women: a cross-sectional study. BMC Med Genet. 2017;18(1):17. doi:10.1186/s12881-017-0378-7. View ArticlePubMedPubMed CentralGoogle Scholar
  4. Maranzatto CF, Miot HA, Miot LD, Meneguin S. Psychometrican analysis and dimensional structure of the Brazilian version of melasma quality of life scale (MELASQoL-BP). An Bras Dermatol. 2016;91(4):422–8. doi:10.1590/abd1806-4841.20165014.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Ishiy PS, Silva LR, Penha MA, Handel AC, Miot HA. Skin diseases reported by workers from UNESP campus at Rubiao Jr, Botucatu-SP (Brazil). An Bras Dermatol 2014;89(3):529-531. doi:10.1590/abd1806-4841.20142875.
  6. Miot LD, Miot HA, Polettini J, Silva MG, Marques ME. Morphologic changes and the expression of alpha-melanocyte stimulating hormone and melanocortin-1 receptor in melasma lesions: a comparative study. Am J Dermatopathol. 2010;32(7):676–82. doi:10.1097/DAD.0b013e3181cd4396. View ArticlePubMedGoogle Scholar
  7. Brianezi G, Handel AC, Schmitt JV, Miot LD, Miot HA. Changes in nuclear morphology and chromatin texture of basal keratinocytes in melasma. J Eur Acad Dermatol Venereol. 2015;29(4):809–12. doi:10.1111/jdv.12453. View ArticlePubMedGoogle Scholar
  8. Lee AY. Recent progress in melasma pathogenesis. Pigment Cell Melanoma Res. 2015;28(6):648–60. doi:10.1111/pcmr.12404. View ArticlePubMedGoogle Scholar
  9. Doddaballapur S. Microneedling with dermaroller. J Cutan Aesthet Surg. 2009;2(2):110–1. doi:10.4103/0974-2077.58529. View ArticlePubMedPubMed CentralGoogle Scholar
  10. Lima Ede A, Lima Mde A, D. T. Microneedling: experimental study and classification of the resulting injury. Surg Cosm Dermatol 2013;5(2):110-114.Google Scholar
  11. Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A Comprehensive Review. Dermatol Surg. 2017;43(3):321–39. doi:10.1097/DSS.0000000000000924.View ArticlePubMedGoogle Scholar
  12. Cohen BE, Elbuluk N. Microneedling in skin of color: a review of uses and efficacy. J Am Acad Dermatol. 2016;74(2):348–55. doi:10.1016/j.jaad.2015.09.024.View ArticlePubMedGoogle Scholar
  13. Lima Ede A. Microneedling in facial recalcitrant melasma: report of a series of 22 cases. An Bras Dermatol. 2015;90(6):919–21. doi:10.1590/abd1806-4841.20154748.View ArticlePubMedGoogle Scholar
  14. Takiwaki H, Miyamoto H, Ahsan K. A simple method to estimate CIE-L*a*b* values of the skin from its videomicroscopic image. Skin Res Technol. 1997;3(1):42–4. doi:10.1111/j.1600-0846.1997.tb00158.x.View ArticlePubMedGoogle Scholar
  15. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, et al. Reliability assessment and validation of the Melasma area and severity index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78–83. doi:10.1016/j.jaad.2009.10.051.View ArticlePubMedGoogle Scholar
  16. Cestari TF, Balkrishann R, Weber MB, Prati C, Menegon DB, Mazzott NG, et al. Translation and cultural adaptation to Portuguese of a quality of life questionnaire for patients with melasma. Med Cutan Iber Lat Am. 2006;34:270–4.Google Scholar
  17. Miot HA. Assessing normality of data in clinical and experimental trials. J Vasc Bras. 2017;16(2):88–91. doi:10.1590/1677-5449.041117.View ArticleGoogle Scholar
  18. Norman GR, Streiner DL. Biostatistics: the bare essentials. 4th ed. Shelton: PMPH-USA; 2014.Google Scholar
  19. Miot HA. Sample size in clinical and experimental trials. J Vasc Bras. 2011;10(4):275–8. doi:10.1590/S1677-54492011000400001.View ArticleGoogle Scholar
  20. Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida AR, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2006;156(Suppl 1):13–20. doi:10.1111/j.1365-2133.2006.07591.x.View ArticlePubMedGoogle Scholar
  21. Torres-Alvarez B, Mesa-Garza IG, Castanedo-Cazares JP, Fuentes-Ahumada C, Oros-Ovalle C, Navarrete-Solis J, et al. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol. 2011;33(3):291–5. doi:10.1097/DAD.0b013e3181ef2d45. View ArticlePubMedGoogle Scholar
  22. Byun JW, Park IS, Choi GS, Shin J. Role of fibroblast-derived factors in the pathogenesis of melasma. Clin Exp Dermatol. 2016;41(6):601–9. doi:10.1111/ced.12874. View ArticlePubMedGoogle Scholar
  23. Miot HA, Brianezi G. Morphometric analysis of dermal collagen by color clusters segmentation. An Bras Dermatol. 2010;85(3):361–4. doi:10.1590/S0365-05962010000300010. View ArticlePubMedGoogle Scholar
  24. Ramaut L, Hoeksema H, Pirayesh A, Stillaert F, Monstrey S. Microneedling: where do we stand now? A systematic review of the literature. J Plast Reconstr Aesthet Surg. 2017 (ahead of print). doi:S1748–6815(17)30250–4.Google Scholar
  25. Alster TS, Graham PM. Microneedling: A Review and Practical Guide. Dermatol Surg. 2017 (ahead of print). doi:10.1097/DSS.0000000000001248.
  26. Tamega Ade A, Miot HA, Moco NP, Silva MG, Marques ME, Miot LD. Gene and protein expression of oestrogen-beta and progesterone receptors in facial melasma and adjacent healthy skin in women. Int J Cosmet Sci. 2015;37(2):222–8. https://doi.org/10.1111/ics.12186.View ArticlePubMedGoogle Scholar
  27. Lee DJ, Park KC, Ortonne JP, Kang HY. Pendulous melanocytes: a characteristic feature of melasma and how it may occur. Br J Dermatol. 2012;166(3):684–6. doi:10.1111/j.1365-2133.2011.10648.x. View ArticlePubMedGoogle Scholar
  28. Bhawan J, Grimes P, Pandya AG, Keady M, Byers HR, Guevara IL, et al. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. Am J Dermatopathol. 2009;31(8):794–8. https://doi.org/10.1097/DAD.0b013e3181a9070d. View ArticlePubMedGoogle Scholar
  29. Lev-Tov H, Larsen L, Zackria R, Chahal H, Eisen DB, Sivamani RK. Microneedle-assisted incubation during aminolaevulinic acid photodynamic therapy of actinic keratoses: a randomized controlled evaluator-blind trial. Br J Dermatol. 2017;176(2):543–5. doi:10.1111/bjd.15116. View ArticlePubMedGoogle Scholar
  30. Sivamani RK, Liepmann D, Maibach HI. Microneedles and transdermal applications. Expert Opin Drug Deliv. 2007;4(1):19–25. https://doi.org/10.1517/17425247.4.1.19.View ArticlePubMedGoogle Scholar
  31. Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S, Dongare A, et al. A randomised, open-label, comparative study of Tranexamic acid microinjections and Tranexamic acid with microneedling in patients with Melasma. J Cutan Aesthet Surg. 2013;6(3):139–43. doi:10.4103/0974-2077.118403.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Ustuner P, Balevi A, Ozdemir M. A split-face, investigator-blinded comparative study on the efficacy and safety of Q-switched Nd:YAG laser plus microneedling with vitamin C versus Q-switched Nd:YAG laser for the treatment of recalcitrant melasma. J Cosmet Laser Ther. 2017:1–8. doi:10.1080/14764172.2017.1342036.
  33. Kunachak S, Leelaudomlipi P, Wongwaisayawan S. Dermabrasion: a curative treatment for melasma. Aesthet Plast Surg. 2001;25(2):114–7. doi:10.1007/s002660010107.View ArticleGoogle Scholar
  34. Bonati LM, Epstein GK, Strugar TL. Microneedling in all skin types: a review. J Drugs Dermatol. 2017;16(4):308–13.PubMedGoogle Scholar
  35. Ornelas J, Foolad N, Shi V, Burney W, Sivamani RK. Effect of microneedle pretreatment on topical anesthesia: a randomized clinical trial. JAMA Dermatol. 2016;152(4):476–7. doi:10.1001/jamadermatol.2015.5544.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement

BMC Dermatology

ISSN: 1471-5945

Contact us